跳至主要内容
临床试验/NCT04803240
NCT04803240已完成不适用

Survey: Evaluation of Ocular Surface Disease Symptoms and Patient Satisfaction With Thealoz® Duo After 84 Days of Daily Treatment

Laboratoires Thea1 个研究点 分布在 1 个国家目标入组 310 人开始时间: 2019年4月1日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
310
试验地点
1
主要终点
OSDI

研究概览

简要总结

Multi-centre, international, non-interventional, prospective survey

详细描述

To assess after 84 days, on a large scale patient population, the evaluation of ocular surface diseases and the satisfaction of dry eye disease (DED) treatment naïve patients or those who had to switch for tolerance, dissatisfaction or efficacy reasons to Thealoz® Duo.

研究设计

研究类型
Observational
观察模型
Other
时间视角
Prospective

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • All dry eye patients who require artificial tears or need to change their current artificial tears for any reason (i.e. due to dissatisfaction or low efficacy, etc...)
  • Outpatients of either sex, aged at least 18 years
  • Patients informed of the objectives of the survey and agreeing to participate.

排除标准

  • Use of cyclosporine, lifitegrast, tacrolimus, sirolimus within last 3 months and during the survey
  • Use of topical ophthalmological treatments (glaucoma, etc...)
  • Use of lacrimal plugs
  • Ocular surgery in the last 12 months
  • Concomitant use of corticosteroids
  • Concomitant use of autologous serum or any blood derivatives
  • Severe blepharitis
  • Severe dry eye associated to
  • Eyelid malposition
  • Corneal dystrophy
  • Ocular neoplasia
  • Sjogren syndrome
  • Any systemic pathologies
  • Pregnancy/lactation

结局指标

主要结局

OSDI

时间窗: 84 days

Change from baseline for patient symptoms using the ocular surface disease index (OSDI©) questionnaire at Day 84. The OSDI is assessed on a scale of 0 to 100, with higher scores representing greater disability.

次要结局

未报告次要终点

研究者

申办方类型
Industry
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验